07/12/2017
Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Zealand Pharma A/S ("Zealand") announces the initiation of the second Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of severe hypoglycemia in patients with Type 1 Diabetes (T1DM). [...]
